A scalable system for production of functional pancreatic progenitors from human embryonic stem cells.
Clicks: 376
ID: 76010
2012
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
376 views
40 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #339 of 2,056 articles by views in PloS one
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 2,056 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Development of a human embryonic stem cell (hESC)-based therapy for type 1 diabetes will require the translation of proof-of-principle concepts into a scalable, controlled, and regulated cell manufacturing process. We have previously demonstrated that hESC can be directed to differentiate into pancreatic progenitors that mature into functional glucose-responsive, insulin-secreting cells in vivo. In this study we describe hESC expansion and banking methods and a suspension-based differentiation system, which together underpin an integrated scalable manufacturing process for producing pancreatic progenitors. This system has been optimized for the CyT49 cell line. Accordingly, qualified large-scale single-cell master and working cGMP cell banks of CyT49 have been generated to provide a virtually unlimited starting resource for manufacturing. Upon thaw from these banks, we expanded CyT49 for two weeks in an adherent culture format that achieves 50-100 fold expansion per week. Undifferentiated CyT49 were then aggregated into clusters in dynamic rotational suspension culture, followed by differentiation en masse for two weeks with a four-stage protocol. Numerous scaled differentiation runs generated reproducible and defined population compositions highly enriched for pancreatic cell lineages, as shown by examining mRNA expression at each stage of differentiation and flow cytometry of the final population. Islet-like tissue containing glucose-responsive, insulin-secreting cells was generated upon implantation into mice. By four- to five-months post-engraftment, mature neo-pancreatic tissue was sufficient to protect against streptozotocin (STZ)-induced hyperglycemia. In summary, we have developed a tractable manufacturing process for the generation of functional pancreatic progenitors from hESC on a scale amenable to clinical entry.
| Reference Key |
schulz2012aplos
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Schulz, Thomas C;Young, Holly Y;Agulnick, Alan D;Babin, M Josephine;Baetge, Emmanuel E;Bang, Anne G;Bhoumik, Anindita;Cepa, Igor;Cesario, Rosemary M;Haakmeester, Carl;Kadoya, Kuniko;Kelly, Jonathan R;Kerr, Justin;Martinson, Laura A;McLean, Amanda B;Moorman, Mark A;Payne, Janice K;Richardson, Mike;Ross, Kelly G;Sherrer, Eric S;Song, Xuehong;Wilson, Alistair Z;Brandon, Eugene P;Green, Chad E;Kroon, Evert J;Kelly, Olivia G;D'Amour, Kevin A;Robins, Allan J; |
| Journal | PloS one |
| Year | 2012 |
| DOI |
10.1371/journal.pone.0037004
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.